Abstract
The pharmacokinetics of 2,000 mg of sulfadiazine administered twice daily (BID) versus those of 1,000 mg administered four times a day were compared in eight human immunodeficiency virus-infected patients. No differences in pharmacokinetic parameters were detected between the regimens. These data provide a pharmacokinetic rationale for BID dosing of sulfadiazine for the treatment and suppression of toxoplasmosis.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Anti-Infective Agents / administration & dosage
-
Anti-Infective Agents / blood
-
Anti-Infective Agents / pharmacokinetics*
-
Area Under Curve
-
Cross-Over Studies
-
HIV Infections / complications
-
HIV Infections / metabolism*
-
Half-Life
-
Humans
-
Models, Biological
-
Sulfadiazine / administration & dosage
-
Sulfadiazine / blood
-
Sulfadiazine / pharmacokinetics*
-
Toxoplasmosis / drug therapy
-
Toxoplasmosis / etiology
Substances
-
Anti-Infective Agents
-
Sulfadiazine